Replies to post #243272 on Biotech Values

[DewDiligence]

“Despite the market size for B-NHL being at least five times the size of ALL, B-NHL has a smaller pipeline of cell therapies…”

indolent NHL, which comprises a large portion of the NHL market, is an especially tough nut to crack, and this explains, in part, the (relative to ALL) dearth of NHL cell therapies in development.

[swampboots]

I wonder if I can say, bring on all the me-toos, so one day this fictional headline would be a reality?:

The major breakthrough of a single gene therapy platform utilizing the brilliant success in identifying all the proteins or processes which have limited previous effectiveness, because they were either not eliminated or introduced in the proper way, have finally solved the dilemma of bringing this gene therapy platform in a position of peer validated eminence to garner the financial capacity to focus balancing all of the necessary manufacturing requirements with the goal of drastically reduced cost.